Dawn A. Brooks

3.5k total citations · 1 hit paper
26 papers, 651 citations indexed

About

Dawn A. Brooks is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Dawn A. Brooks has authored 26 papers receiving a total of 651 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 10 papers in Psychiatry and Mental health and 8 papers in Pharmacology. Recurrent topics in Dawn A. Brooks's work include Alzheimer's disease research and treatments (14 papers), Dementia and Cognitive Impairment Research (8 papers) and Cholinesterase and Neurodegenerative Diseases (8 papers). Dawn A. Brooks is often cited by papers focused on Alzheimer's disease research and treatments (14 papers), Dementia and Cognitive Impairment Research (8 papers) and Cholinesterase and Neurodegenerative Diseases (8 papers). Dawn A. Brooks collaborates with scholars based in United States, United Kingdom and Sweden. Dawn A. Brooks's co-authors include David R. Williams, Patrick D. Lowder, Martin A. Berliner, John R. Sims, James R. McCarthy, Mark A. Mintun, Cynthia Evans, Scott W. Andersen, Sergey Shcherbinin and Mary Peters and has published in prestigious journals such as Journal of the American Chemical Society, Neurology and Journal of Medicinal Chemistry.

In The Last Decade

Dawn A. Brooks

23 papers receiving 638 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease

2025 29 citations Jennifer A. Zimmer, Paul Ardayfio et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn A. Brooks United States	11	342	196	182	125	78	26	651
Andrew P. Degnan United States	13	304 0.9×	185 0.9×	59 0.3×	68 0.5×	45 0.6×	23	558
Emanuele Gabellieri Italy	10	129 0.4×	100 0.5×	158 0.9×	139 1.1×	35 0.4×	12	403
Mark A. Sanner United States	13	446 1.3×	217 1.1×	65 0.4×	78 0.6×	25 0.3×	21	758
Suman Rakhit United States	17	367 1.1×	237 1.2×	148 0.8×	43 0.3×	32 0.4×	27	635
David K. Dean United Kingdom	15	442 1.3×	304 1.6×	79 0.4×	58 0.5×	18 0.2×	28	768
Elliott D. Bayle United Kingdom	10	249 0.7×	207 1.1×	71 0.4×	64 0.5×	17 0.2×	10	544
William F. Goure United States	10	188 0.5×	117 0.6×	226 1.2×	97 0.8×	19 0.2×	11	500
Arthur Y. Shaw United States	18	493 1.4×	240 1.2×	61 0.3×	125 1.0×	11 0.1×	29	729
Daniel V. Paone United States	15	744 2.2×	283 1.4×	81 0.4×	83 0.7×	216 2.8×	27	1.1k
Hayato Fukuda Japan	18	322 0.9×	213 1.1×	64 0.4×	66 0.5×	10 0.1×	61	848

Countries citing papers authored by Dawn A. Brooks

Since Specialization

Citations

This map shows the geographic impact of Dawn A. Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn A. Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn A. Brooks more than expected).

Fields of papers citing papers by Dawn A. Brooks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn A. Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn A. Brooks. The network helps show where Dawn A. Brooks may publish in the future.

Co-authorship network of co-authors of Dawn A. Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn A. Brooks. A scholar is included among the top collaborators of Dawn A. Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn A. Brooks. Dawn A. Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gueorguieva, Ivelina, Kay Hoong Chow, Laiyi Chua, et al.. (2025). Donanemab exposure‐response in early symptomatic Alzheimer's disease. Alzheimer s & Dementia. 21(7). e70491–e70491. 5 indexed citations

Zimmer, Jennifer A., John R. Sims, Cynthia Evans, et al.. (2025). Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension. The Journal of Prevention of Alzheimer s Disease. 13(2). 100446–100446.

Wang, Hong, Emel Serap Monkul Nery, Paul Ardayfio, et al.. (2025). The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. The Journal of Prevention of Alzheimer s Disease. 12(8). 100266–100266. 2 indexed citations

Lu, Ming, Emily C. Collins, Sergey Shcherbinin, et al.. (2025). Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease. JAMA Neurology. 82(12). 1251–1251. 2 indexed citations

Zimmer, Jennifer A., Paul Ardayfio, Hong Wang, et al.. (2025). Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease. JAMA Neurology. 82(5). 461–461. 29 indexed citations breakdown →

Wang, Hong, Emel Serap Monkul Nery, Paul Ardayfio, et al.. (2025). Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer s & Dementia. 21(4). e70062–e70062. 10 indexed citations

Salloway, Stephen, Michelle Papka, Hong Wang, et al.. (2025). TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease. Alzheimer s & Dementia. 21(5). e70293–e70293. 5 indexed citations

Mullins, Garrett R., Paul Ardayfio, Ivelina Gueorguieva, et al.. (2025). Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(3). e70149–e70149.

Greenberg, Steven M., Ming‐Chi Lu, Alessandro Biffi, et al.. (2024). ARIA Insights from the Donanemab Trials (P1-9.001). Neurology. 102(7_supplement_1). 3339–3339. 5 indexed citations

10.

Atri, Alireza, Alette M. Wessels, Erin Doty, et al.. (2024). Clinical Relevance of Donanemab Treatment (S1.004). Neurology. 102(7_supplement_1).

11.

Mintun, Mark A., Craig Ritchie, Paul R. Solomon, et al.. (2023). Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial. Alzheimer s & Dementia. 19(S24). 6 indexed citations

12.

Shcherbinin, Sergey, Ivelina Gueorguieva, Cynthia Evans, et al.. (2023). Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials. Alzheimer s & Dementia. 19(S14). 3 indexed citations

13.

Evans, Cynthia, JonDavid Sparks, Scott W. Andersen, et al.. (2023). APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials. Alzheimer s & Dementia. 19(12). 5407–5417. 8 indexed citations

14.

Wang, Hong, Stephen Salloway, Michelle Papka, et al.. (2023). TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months. Alzheimer s & Dementia. 19(S24). e082529–e082529. 5 indexed citations

15.

Salloway, Stephen, Michelle Papka, Hong Wang, et al.. (2023). TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease. BJPsych Open. 9(S1). S67–S67. 10 indexed citations

16.

Salloway, Stephen, Michelle Papka, Hong Wang, et al.. (2023). TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease (S26.009). Neurology. 100(17_supplement_2). 4 indexed citations

17.

Shcherbinin, Sergey, Cynthia Evans, Ming‐Chi Lu, et al.. (2022). Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes. JAMA Neurology. 79(10). 1015–1015. 117 indexed citations

18.

Williams, David R., Dawn A. Brooks, & Martin A. Berliner. (1999). Total Synthesis of (−)-Hennoxazole A. Journal of the American Chemical Society. 121(20). 4924–4925. 65 indexed citations

19.

Williams, David R., Dawn A. Brooks, Kevin G. Meyer, & Marty Pagel. (1998). Regioselective ring metalation in [2,4]-bisoxazoles. Tetrahedron Letters. 39(44). 8023–8026. 10 indexed citations

20.

Williams, David R., et al.. (1997). Studies of mild dehydrogenations in heterocyclic systems. Tetrahedron Letters. 38(3). 331–334. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact